昭衍新药2023年年报点评:盈利能力短期承压,国际化持续推进
JOINN(603127) 国泰君安·2024-04-09 16:00
研究 可更新 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------|-----------------------------------------------------------------------------------------|---------------------|----------------------------------|---------------------------------------------------|-------------|-------------------------------|-----------------------------|---------------|-----------------| | [Table_Main[ 昭 TIna | 衍 fbole] 新 T 药 itle] (603127) | | | [Table_industryInfo] | | \n[ 评 Tab 级 le | : Inv ...